Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reimagines Technology to Create Better Cancer Outcomes

• Archaic technology contributes to dismal recurrence rate in bladder cancer
• Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery
• There is potential to extend this technology to virtually other endoscopic procedures

The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and therapeutics. However, bladder cancer has the highest recurrence rate of all cancers. 50% of bladder cancers recur, attacking anew from a just few cells that were missed during surgery. Surgeons do the best they can, but with outdated technology they can’t clearly visualize inside the bladder, clearly identify and then remove potentially malignant cells. This dilemma is about to be rectified with a breakthrough new technology that, will gives surgeons, not only the ability to clearly see inside the bladder, but also more easily identify and surgically remove all the cancer

With bladder cancer as its first target, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) intends to change the dismal outcomes of bladder cancer recurrence with its i/Blue Imaging(TM) System. The company’s patented, ultrasensitive imaging technology aims to revolutionize the archaic techniques currently used in treating bladder cancer and extend the technology to multiple other surgical procedures.

Conventional diagnostic procedures for visualizing bladder cancer during surgery allow surgeons to see inside the body with a thin, lighted, flexible tube which uses white light to illuminate the bladder. White light images show a full picture of the bladder but do not effectively highlight cancerous cells which can be left behind to attack again. A recent advancement uses blue-filtered white light to better detect tumors and cancerous cells not seen with white light. However, surgeons cannot use blue light images to operate. Blue cystoscope images aren’t in real time and the position in the bladder can be confusing, requiring the surgeon to manually switchback and forth from white to blue light images These technologies remain lacking and recurrence remains at high levels. 600,000 people live in fear that their cancer will return, unfortunately about half of them will have their worst fears realized.

Imagin Medical’s i/Blue Imaging System rectifies the limitations of white and blue light cystoscopies. Combining both the white and blue light with an FDA approved imaging agent, the i/Blue System displays side-by-side images in real-time, eliminating the need to switch back and forth between the two images. Using the i/Blue System, surgeons can now see the full landscape of the bladder and identify malignant cells in a single, unified process. This technological advancement is expected to drive down the dismal recurrence of bladder cancers and deliver hope to the tens of thousands that suffer with the disease.

Imagin Medical’s unique i/Blue Imaging System can attach to virtually any endoscope model currently in use which creates a plug and play system adaptable to almost any clinical setting which opens vast new markets for the company’s technology. The FDA approval process is underway, and the company’s intellectual property is well-protected.

Imagin Medical has reimagined technology to create better outcomes for cancer patients, and as the technology gains traction it may well become the new standard of care for bladder cancer and other endoscopic procedures.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.